Full metadata record
Appears in Collections:
DC FieldValueLanguage
dc.creatorStegbauer, C. (Constance)-
dc.creatorFalivena, C. (Camilla)-
dc.creatorMoreno, A. (Ariadna)-
dc.creatorHentschel, A. (Anna)-
dc.creatorRosenmöller, M. (Magda)-
dc.creatorSzecsenyi, J. (Joachim)-
dc.creatorSchliess, F. (Freimut)-
dc.identifier.citationStegbauer, C., Falivena, C., Moreno, A. et al. Costs and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studies. BMC Health Serv Res 20, 1043 (2020). https://doi.org/10.1186/s12913-020-05897-wes_ES
dc.description.abstractBackground: Type 2 diabetes represents an increasingly critical challenge for health policy worldwide. It absorbs massive resources from both patients and national economies to sustain direct costs of the treatment of type 2 diabetes and its complications and indirect costs related to work loss and wages. More recently, there are innovations based on remote control and personalised programs that promise a more cost-effective diabetes management while reducing diabetes-related complications. In such a context, this work attempts to update cost analysis reviews on type 2 diabetes, focusing on France and Germany, in order to explore most significant cost drivers and cost-saving opportunities through innovations in diabetes care. Although both countries approach care delivery differently, France and Germany represent the primary European markets for diabetes technologies. Methods: A systematic review of the literature listed in MEDLINE, Embase and EconLit has been carried out. It covered interventional, observational and modelling studies on expenditures for type 2 diabetes management in France or Germany published since 2012. Included articles were analysed for annual direct, associated and indirect costs of type 2 diabetes patients. An appraisal of study quality was performed. Results were summarised narratively. Results: From 1260 records, the final sample was composed of 24 papers selected according to predefined inclusion/exclusion criteria. Both France and Germany revealed a predominant focus on direct costs. Comparability was limited due to different study populations and cost categories used. Indirect costs were only available in Germany. According to prior literature, reported cost drivers are hospitalisation, prescriptions, higher HbA1c and BMI, treatment with insulin and complications, all indicators of disease severity. The diversity of available data and included costs limits the results and may explain the differences found. Conclusions: Complication prevention and glycaemic control are widely recognized as the most effective ways to control diabetes treatment costs. The value propositions of self-based supports, such as hybrid closed-loop metabolic systems, already implemented in type 1 diabetes management, are the key points for further debates and policymaking, which should involve the perspectives of caregivers, patients and payers.es_ES
dc.description.sponsorshipThis systematic review is part of an activity (CLOSE project, Grant Agreement No. 19440) that has received funding from EIT Health. EIT Health is supported by the European Institute of Innovation and Technology (EIT), a body of the European Union receives support from the European Unioń s Horizon 2020 Research and innovation programme. The EIT Health had no role in the study design, search strategy, selection of papers, analysis and interpretation of results or in the decision to publish the results or writing the manuscript. The publication of the results was not contingent on EIT Health approval or censorship of the manuscript.es_ES
dc.subjectHealth care costses_ES
dc.subjectDiabetes mellitus type 2es_ES
dc.titleCosts and its drivers for diabetes mellitus type 2 patients in France and Germany: a systematic review of economic studieses_ES
dc.publisher.placeReino Unidoes_ES
dc.description.noteThis article is licensed under a Creative Commons Attribution 4.0 International Licensees_ES
dadun.citation.publicationNameBMC Health Services Researches_ES

Files in This Item:
1.01 MB
Adobe PDF

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.